JPWO2023092107A5 - - Google Patents
Info
- Publication number
- JPWO2023092107A5 JPWO2023092107A5 JP2024529341A JP2024529341A JPWO2023092107A5 JP WO2023092107 A5 JPWO2023092107 A5 JP WO2023092107A5 JP 2024529341 A JP2024529341 A JP 2024529341A JP 2024529341 A JP2024529341 A JP 2024529341A JP WO2023092107 A5 JPWO2023092107 A5 JP WO2023092107A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- halo
- cancer
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281508P | 2021-11-19 | 2021-11-19 | |
| US63/281,508 | 2021-11-19 | ||
| USPCT/US2022/080165 | 2022-11-18 | ||
| PCT/US2022/080165 WO2023092088A1 (en) | 2021-11-19 | 2022-11-18 | Cdk2 inhibitors and methods of making and using same |
| PCT/US2022/080199 WO2023092107A1 (en) | 2021-11-19 | 2022-11-19 | Cdk2 inhibitors and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540483A JP2024540483A (ja) | 2024-10-31 |
| JP2024540483A5 JP2024540483A5 (https=) | 2025-11-27 |
| JPWO2023092107A5 true JPWO2023092107A5 (https=) | 2025-11-27 |
Family
ID=84901264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529341A Pending JP2024540483A (ja) | 2021-11-19 | 2022-11-19 | Ｃｄｋ２阻害剤及びその製造方法及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250074895A1 (https=) |
| EP (1) | EP4433470A1 (https=) |
| JP (1) | JP2024540483A (https=) |
| CN (1) | CN118265706A (https=) |
| WO (2) | WO2023092088A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| CN119072471A (zh) * | 2022-04-28 | 2024-12-03 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| CN120239698A (zh) * | 2022-11-17 | 2025-07-01 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| US20240317777A1 (en) * | 2023-02-23 | 2024-09-26 | Accutar Biotechnology Inc. | Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors |
| WO2025062334A1 (en) * | 2023-09-20 | 2025-03-27 | Beigene Switzerland Gmbh | 4-((5-(3-(4-(pyridin-2-yl)cyclopentyl)-1 h-pyrazol-3-yl)amino)-benzenesulfonamide derivatives and similar compounds as cdk inhibitors for the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154016A0 (en) * | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| WO2020050653A1 (ko) | 2018-09-05 | 2020-03-12 | 삼성전자 주식회사 | 이동 통신 시스템에서 papr 감소를 위한 기준 신호 시퀀스 생성 방법 및 장치 |
| CN113330000B (zh) * | 2019-01-31 | 2024-12-24 | 辉瑞公司 | 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物 |
-
2022
- 2022-11-18 WO PCT/US2022/080165 patent/WO2023092088A1/en not_active Ceased
- 2022-11-19 JP JP2024529341A patent/JP2024540483A/ja active Pending
- 2022-11-19 US US18/710,715 patent/US20250074895A1/en active Pending
- 2022-11-19 EP EP22840847.2A patent/EP4433470A1/en active Pending
- 2022-11-19 WO PCT/US2022/080199 patent/WO2023092107A1/en not_active Ceased
- 2022-11-19 CN CN202280076541.5A patent/CN118265706A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laali et al. | Novel fluorinated curcuminoids and their pyrazole and isoxazole derivatives: Synthesis, structural studies, Computational/Docking and in-vitro bioassay | |
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| JP2022062168A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| KR20240044469A (ko) | 경구 생체이용률이 높은 jak 억제제 | |
| JP2005521713A (ja) | 血管新生阻害剤 | |
| JPWO2019191470A5 (https=) | ||
| KR20110025741A (ko) | 퀴나졸린 유도체 | |
| CA2716518A1 (en) | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members | |
| JPWO2023092107A5 (https=) | ||
| CN113082210B (zh) | 一种肿瘤化疗药物组合物 | |
| Zhang et al. | Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JPWO2023278326A5 (https=) | ||
| Zhu et al. | Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer | |
| JPWO2021195128A5 (https=) | ||
| WO2023143147A1 (zh) | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 | |
| Chen et al. | Discovery of pyrrolo [2, 3-d] pyrimidine-based molecules as a Wee1 inhibitor template | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| US20230399325A1 (en) | Succinate and crystal form thereof as therapeutics | |
| CN101291675B (zh) | 抗癌组合药物 | |
| WO2020172906A1 (zh) | 一种新型pan-RAF激酶抑制剂及其用途 | |
| CN111718350B (zh) | 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用 | |
| CA3113408A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
| EP4112608A1 (en) | Aryl-fused isoselenazole compound containing tetrazine substituent, synthesis method therefor, and use thereof |